Effect of adrenocorticotrophic hormone and androst-5-en-17-on-3beta-YL sulphate administration to the mother on urinary oestrogen excretion in late human pregnancy.
D015068:17-Ketosteroids / Q000652:urine; D000309:Adrenal Insufficiency / Q000188:drug therapy; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology*; D000757:Anencephaly / Q000652:urine; D003687:Dehydroepiandrosterone / Q000494:pharmacology* / Q000502:physiology; D004958:Estradiol / Q000652:urine*; D004964:Estriol / Q000652:urine*; D004967:Estrogens / Q000096:biosynthesis; D004970:Estrone / Q000652:urine*; D005260:Female; D006801:Humans; D010920:Placenta / Q000378:metabolism; D011239:Prednisolone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011247:Pregnancy
D015068:17-Ketosteroids; D004967:Estrogens; D004970:Estrone; D003687:Dehydroepiandrosterone; D004958:Estradiol; D000324:Adrenocorticotropic Hormone; D011239:Prednisolone; D004964:Estriol; D011241:Prednisone